Glucocorticoid therapy and the risk of infection in patients with newly diagnosed autoimmune disease

Medicine (United States)

Volumn 92, Issue 5, 2013, Pages 285-293

  Migita, Kiyoshi ^a   Sasaki, Yasuharu ^a   Ishizuka, Naoki ^a   Arai, Toru ^a   Kiyokawa, Tetsuyuki ^a   Suematsu, Eiichi ^a   Yoshimura, Mitsuhiro ^a   Kawabe, Yojiro ^a   Matsumura, Ryutaro ^a   Akagawa, Shinobu ^a   Mori, Shunsuke ^a   Shirai, Masahiro ^a   Watanabe, Yukio ^a   Minami, Naoya ^a   Soga, Takayoshi ^a   Owan, Isoko ^a   Ohshima, Shiro ^a   Yoshizawa, Shigeru ^a   Matsui, Toshihiro ^a   Tohma, Shigeto ^a   Bito, Seiji ^a   more..

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CORTISONE; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; TRIAMCINOLONE;

ADULT; ADULT ONSET STILL DISEASE; AGED; ANAPHYLACTOID PURPURA; ARTICLE; AUTOIMMUNE BULLOUS DISEASE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE PANCREATITIS; AVASCULAR NECROSIS; BACTERIAL INFECTION; BEHCET DISEASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC GLOMERULONEPHRITIS; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DERMATOMYOSITIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG FATALITY; DRUG MEGADOSE; ESOPHAGUS ULCER; FEMALE; FOLLOW UP; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GLOMERULOPATHY; GROUPS BY AGE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; INCIDENCE; INFECTION RISK; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; KARNOFSKY PERFORMANCE STATUS; KIDNEY FAILURE; LIVER FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIXED CONNECTIVE TISSUE DISEASE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYCOSIS; NEPHROTIC SYNDROME; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PEPTIC ULCER; PNEUMOCYSTIS PNEUMONIA; POLYMYOSITIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PSYCHOSIS; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RESPIRATORY FAILURE; RISK FACTOR; SJOEGREN SYNDROME; STEROID PSYCHOSIS; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TUBERCULOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VASCULITIS;

EID: 85027944054     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0b013e3182a72299     Document Type: Article

References (35)

1. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
2. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624-1632.
3. Bijlsma JW, Saag KG, Buttgereit F, da Silva JA. Developments in glucocorticoid therapy. Rheum Dis Clin North Am. 2005;31:1-17.
4. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993;119:1198-1208.
5. Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, Kirwan J, Kohler L, Van Riel P, Vischer T, Bijlsma JW. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61:718-722.
6. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50:3408-3417.
7. Caldwell JR, Furst DE. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum. 1991;21:1-11.
8. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CM, Saag KG. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55:420-426.
9. Dale DC, Petersdorf RG. Corticosteroids and infectious diseases. Med Clin North Am. 1973;57:1277-1287.
10. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, de Koning EJ, Buttgereit F, Cutolo M, Capell H, Rau R, Bijlsma JW. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285-293.
11. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-2300.
12. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis. 2007;66:308-312.
13. Garwood F. Fiducial limits for the Poisson distribution. Biometrika. 1936;28:437-442.
14. Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson RH Jr. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis. 1983;148:230-238.
15. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, Choy EH, Cutolo M, Da Silva JA, Esselens G, Guillevin L, Hafstrom I, Kirwan JR, Rovensky J, Russell A, Saag KG, Svensson B, Westhovens R, Zeidler H, Bijlsma JW. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560-1567.
16. Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68:1833-1838.
17. Hwang YG, Saag K. The safety of low-dose glucocorticoids in rheumatic diseases. Clin Exp Rheumatol. 2011;29(5 Suppl 68): S104-S112.
18. Kimberly RP. Mechanisms of action, dosage schedules, and side effects of steroid therapy. Curr Opin Rheumatol. 1991;3:373-379.
19. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362:1828-1838.
20. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-1097.
21. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008;20:131-137.
22. McDougall R, Sibley J, Haga M, Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol. 1994;21:1207-1213.
23. Morand EF. Corticosteroids in the treatment of rheumatologic diseases. Curr Opin Rheumatol. 2000;12:171-177.
24. Nakamura J, Saisu T, Yamashita K, Suzuki C, Kamegaya M, Takahashi K. Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Arthritis Rheum. 2010;62:609-615.
25. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009; 11:R109-R116.
26. Ruyssen-Witrand A, Fautrel B, Saraux A, Le-Loet X, Pham T. Infections induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. 2010; 77:246-251.
27. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96:115-123.
28. Sakuma Y, Katoh T, Owada K, Suzuki H, Sakurai K, Eiro M, Asahi K, Watanabe T. Initial functional status predicts infections during steroid therapy for renal diseases. Clin Nephrol. 2005;63:68-73.
29. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23-43.
30. Schmoor C, Gall C, Stampf S, Graf E. Correction of confounding bias in non-randomized studies by appropriate weighting. Biom J. 2011;53:369-387.
31. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis. 1993;17(Suppl 2):S416-S422.
32. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267:832-837.
33. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11:954-963.
34. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136:1-12.
35. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-770.